Brief: Diamyd Medical Phase IIb Topline Results Demonstrate A Significant Treatment Effect Of Diamyd

Diamyd Medical AB

15/09/2020 09:18

Sept 15 (Reuters) - Diamyd Medical AB  DMYDb.ST :
    * SAID ON MONDAY PHASE IIB TOPLINE RESULTS DEMONSTRATE A
SIGNIFICANT TREATMENT EFFECT OF DIAMYD ®  IN A PREVIOUSLY
IDENTIFIED GENETIC SUBGROUP OF INDIVIDUALS WITH TYPE 1 DIABETES
    * THE REULTS, ENCOMPASSING A TOTAL OF 109 PATIENTS, SHOWED A
STATISTICALLY SIGNIFICANT EFFECT IN THE PREDEFINED HLA (HUMAN
LEUKOCYTE ANTIGEN) SUBGROUP OF TRIAL PARTICIPANTS
    * HIS TRIAL DEMONSTATED A PRESERVATION OF BETA CELL FUNCTION
AT 15
MONTHS POST-DIAGNOSIS, AS MEASURED BY MEAL STIMULATED C-PEPTIDE
    * NO RELATED SEVERE ADVERESE EVENTS WERE OBSERVED IN THE
TRIAL. 
    * BASED ON THESE RESULTS, DIAMYD MEDICAL WILL PURSUE THE HLA
RESTRICTED RESPONDER SUBGROUP IN AN UPCOMING PIVOTAL PHASE III
PROGRAM.
    * THE PRIMARY ENDPOINT, DEFINED AS MEAL STIMULATED C-PEPTIDE
IN
THE ENTIRE TRIAL POPULATION WAS NOT MET

Source text for Eikon:  ID:nWkrbkr0Fc 
Further company coverage:  DMYDb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))